The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19
Open accessAbstract
Background: Severe coronavirus disease 2019 (COVID-19) can manifest in rapid decompensation and respiratory failure with elevated inflammatory markers, consistent with cytokine release syndrome for which IL-6 blockade is an approved treatment. Methods: We assessed effectiveness and safety of IL-6 blockade with tocilizumab in a single-center cohort of patients with COVID-19 requiring mechanical ventilation. The primary endpoint was survival probability postintubation; secondary analyses included an ordinal illness severity scale integrating superinfections. Outcomes in patients who received tocilizumab compared with tocilizumab-untreated controls were evaluated using multivariable Cox regression with propensity score inverse probability of treatment weighting (IPTW). Results: 154 patients were included, of whom 78 received tocilizumab and 76 did not. Median follow-up was 47 days (range, 28–67). Baseline characteristics were similar between groups, although tocilizumab-treated patients were younger (mean: 55 vs 60 years), less likely to have chronic pulmonary disease (10% vs 28%), and had lower D-dimer values at time of intubation (median: 2.4 vs 6.5 mg/dL). In IPTW-adjusted models, tocilizumab was associated with a 45% reduction in hazard of death (HR, .55; 95% CI, .33–.90) and improved status on the ordinal outcome scale [OR per 1-level increase, .58; .36–.94). Although tocilizumab was associated with an increased proportion of patients with superinfections (54% vs 26%; P < .001), there was no difference in 28-day case fatality rate among tocilizumab-treated patients with versus without superinfection (22% vs 15%; P = .42). Staphylococcus aureus accounted for ~50% of bacterial pneumonia. Conclusions: In this cohort of mechanically ventilated COVID-19 patients, tocilizumab was associated with lower mortality despite higher superinfection occurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246 · cited 2×
“Up to 20% of patients with COVID-19 develop severe illness characterized by worsening dyspnea and the need for supplemental oxygen [1].”
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0994 · Cited by 8,249
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Austin, P. C., & Stuart, E. A. (2015) · Statistics in Medicine · doi:10.1002/sim.6607 · Cited by 4,495
Petrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O’Donnell, L., Chernyak, Y., Tobin, K. A., Cerfolio, R. J., Francois, F., & Horwitz, L. I. (2020) · BMJ · doi:10.1136/bmj.m1966 · Cited by 3,054
Multiple imputation of discrete and continuous data by fully conditional specification
van Buuren, S. (2007) · Statistical Methods in Medical Research · doi:10.1177/0962280206074463 · Cited by 2,827 · cited 2×
“Case fatality rates at day 28 were similar among tocilizumab-treated patients who had a superinfection and those who did not (8/37 [22”
Vandenbroucke, J. P., von Elm, E., Altman, D. G., Gøtzsche, P. C., Mulrow, C. D., Pocock, S. J., Poole, C., Schlesselman, J. J., & Egger, M. (2007) · Epidemiology · doi:10.1097/ede.0b013e3181577511 · Cited by 2,779
Effective treatment of severe COVID-19 patients with tocilizumab
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005615117 · Cited by 2,647
Robins, J. (1986) · Mathematical Modelling · doi:10.1016/0270-0255(86)90088-6 · Cited by 2,451 · cited 1×
“…of treatment weighting (IPTW) to create a pseudo-study cohort, where the weighted version can balance off the covariate bias and mimic a randomized treatment assignment situation: the IPT weights for tocilizumab-treated patients = 1/p (treated); for untreated patients = 1/(1 − p [treated]) [23–25].”
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020) · JAMA · doi:10.1001/jama.2020.6019 · Cited by 2,347
Cytokine release syndrome in severe COVID-19
Moore, J. B., & June, C. H. (2020) · Science · doi:10.1126/science.abb8925 · Cited by 1,912 · cited 3×
“A secondary endpoint assessed status at day 28 on a 6-level ordinal scale of illness severity, including bloodstream infection and pneumonia: (1) discharged alive, (2) hospitalized/off ventilator without superinfection, (3) hospitalized/off ventilator with superinfection, (4) hospitalized/mechanically ventilated witho…”
Immortal Time Bias in Pharmacoepidemiology
Suissa, S. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwm324 · Cited by 1,708
McGonagle, D., Sharif, K., O'Regan, A., & Bridgewood, C. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102537 · Cited by 1,654
Tocilizumab treatment in COVID‐19: A single center experience
Luo, P., Liu, Y., Qiu, L., Liu, X., Liu, D., & Li, J. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25801 · Cited by 1,237
Rice, T. W., Wheeler, A. P., Bernard, G. R., Hayden, D. L., Schoenfeld, D. A., & Ware, L. B. (2007) · Chest · doi:10.1378/chest.07-0617 · Cited by 820
Teachey, D. T., Rheingold, S. R., Maude, S. L., Zugmaier, G., Barrett, D. M., Seif, A. E., Nichols, K. E., Suppa, E. K., Kalos, M., Berg, R. A., et al. (2013) · Blood · doi:10.1182/blood-2013-02-485623 · Cited by 613
The Role of Interleukin 6 During Viral Infections
Velazquez-Salinas, L., Verdugo-Rodriguez, A., Rodriguez, L. L., & Borca, M. V. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01057 · Cited by 526
Trends in Mortality for Medicare Beneficiaries Treated in the Emergency Department From 2009 to 2016
Burke, L. G., Epstein, S. K., Burke, R. C., Orav, E. J., & Jha, A. K. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.4866 · Cited by 382
Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity
Bester, J., & Pretorius, E. (2016) · Scientific Reports · doi:10.1038/srep32188 · Cited by 305
Sciascia, S., Aprà, F., Baffa, A., Baldovino, S., Boaro, D., Boero, R., Bonora, S., Calcagno, A., Cecchi, I., Cinnirella, G., et al. (2020) · PubMed · Cited by 303
Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
Capra, R., De Rossi, N., Mattioli, F., Romanelli, G., Scarpazza, C., Sormani, M. P., & Cossi, S. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.05.009 · Cited by 271
Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients
Klopfenstein, T., Zayet, S., Lohse, A., Balblanc, J.-C., Badie, J., Royer, P.-Y., Toko, L., Mezher, C., Kadiane-Oussou, N. J., Bossert, M., et al. (2020) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2020.05.001 · Cited by 266
Lin, S. H., Wang, L., Myles, B., Thall, P. F., Hofstetter, W. L., Swisher, S. G., Ajani, J. A., Cox, J. D., Komaki, R., & Liao, Z. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.02.015 · Cited by 261
Self-citationThe immunology of COVID-19: is immune modulation an option for treatment?
Zhong, J., Tang, J., Ye, C., & Dong, L. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30120-x · Cited by 236
Robins, J. M. (1987) · Computers & Mathematics with Applications · doi:10.1016/0898-1221(87)90238-0 · Cited by 212
Gritti, G., Raimondi, F., Bottazzi, B., Ripamonti, D., Riva, I., Landi, F., Alborghetti, L., Frigeni, M., Damiani, M., Micò, C., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01299-x · Cited by 210
Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
Antinori, S., Bonazzetti, C., Gubertini, G., Capetti, A., Pagani, C., Morena, V., Rimoldi, S., Galimberti, L., Sarzi-Puttini, P., & Ridolfo, A. L. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102564 · Cited by 183
Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome
Radbel, J., Narayanan, N., & Bhatt, P. J. (2020) · Chest · doi:10.1016/j.chest.2020.04.024 · Cited by 172
IL-6 ameliorates acute lung injury in influenza virus infection
Yang, M.-L., Wang, C.-T., Yang, S.-J., Leu, C.-H., Chen, S.-H., Wu, C.-L., & Shiau, A.-L. (2017) · Scientific Reports · doi:10.1038/srep43829 · Cited by 159
Novel Role of T Cells and IL-6 (Interleukin-6) in Angiotensin II–Induced Microvascular Dysfunction
Senchenkova, E. Y., Russell, J., Yıldırım, A., Granger, D. N., & Gavins, F. N. E. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12286 · Cited by 86
Open source clinical science for emerging infections
Dunning, J. W., Merson, L., Rohde, G. G. U., Gao, Z., Semple, M. G., Tran, D., Gordon, A. C., Olliaro, P., Khoo, S., Bruzzone, R., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70327-x · Cited by 84
Cited by
Interleukin-6 receptor antagonists in critically ill patients with Covid-19.
The REMAP-CAP Investigators (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100433 · Cited by 1,962
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
Stone, J. H., Frigault, M. J., Serling-Boyd, N. J., Fernandes, A. D., Harvey, L., Foulkes, A. S., Horick, N. K., Healy, B. C., Shah, R., Bensaci, A. M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028836 · Cited by 1,362
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
Rosas, I. O., Bräu, N., Waters, M., Go, R. C., Hunter, B. D., Bhagani, S., Skiest, D., Aziz, M. S., Cooper, N., Douglas, I. S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028700 · Cited by 1,125
COVID-19 is, in the end, an endothelial disease
Libby, P., & Lüscher, T. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa623 · Cited by 961
Koehler, P., Bassetti, M., Chakrabarti, A., Chen, S. C. A., Colombo, A. L., Hoenigl, M., Klimko, N., Lass-Flörl, C., Oladele, R. O., Vinh, D. C., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30847-1 · Cited by 951
Metadata
- Authors
- Somers, E. C., Eschenauer, G. A., Troost, J. P., Golob, J. L., Gandhi, T. N., Wang, L., Zhou, N., Petty, L. A., Baang, J. H., Dillman, N. O., Frame, D., Gregg, K. S., Kaul, D. R., Nagel, J., Patel, T. S., Zhou, S., Lauring, A. S., Hanauer, D. A., Martin, E., Sharma, P., Fung, C. M., & Pogue, J. M.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-07-11
- Volume
- 73
- Issue
- 2
- Pages
- e445-e454
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W3041464116
- Cited by
- 497
- References
- 32
- FWCI
- 13.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.